Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Rein Therapeutics, Inc.

NASDAQ: RNTX · Life Sciences · 2 alerts · CIK 1420565

Share price
$0.4000Close, Nov 16
Market cap
$34.5M
Shares outstanding
86.27MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Rein Therapeutics, Inc. filings on SEC EDGAR ↗

8:39 AM ET 8-K
Clinical Trial Data

Rein Therapeutics Clinical Trial Data

Rein Therapeutics announced preliminary blinded Phase 2 data from its RENEW trial evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF). The data showed that 33% of evaluable patients demonstrated improvement in forced vital capacity (FVC) at Week 12, with favorable safety and tolerability observed across the study population.

“As we continue to enroll patients in the study, today’s blinded look at the data shows encouraging lung function trends and a favorable safety and tolerability profile across the study population, reinforcing our confidence in the potential of LTI-03 to deliver a differentiated clinical and safety profile for patients with significant unmet need.”

Brian Windsor, Ph.D., President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.